Sign in
Taking people in United StatesPhase 1

Tests PLN-101095 with pembrolizumab in adults with advanced solid tumors

Tests PLN-101095, alone and with pembrolizumab, in adults with solid tumors that progressed on immunotherapy.

Key facts

Who runs it
Pliant Therapeutics, Inc.
Where
Atlanta, Austin, East Brunswick, Edmonds, Fairfax, Fort Worth, Grand Rapids, Houston, Lake Success, Nashville, New Brunswick, New Haven, San Antonio, Sioux Falls, St Louis, Washington D.C., West Valley City, and Wilson, United StatesSee the 20 sitesAlso in 1 other country, 7 sites
Trial code
Registry title
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Status
Recruiting
Phase
Phase 1
People taking part
124 people, planned
Started
30 Aug 2023
Expected to end
Jun 2030
Type of study
Interventional, 8 groups
Treatments tested
  • PLN-101095
  • Pembrolizumab
Record updated
12 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with an advanced or spread solid tumor whose cancer grew while on an anti-PD-1 or anti-PD-L1 treatment.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Advanced or metastatic solid tumor, confirmed by tissue or cell tests, with at least 1 measurable lesion by RECIST v1.1 and estimated survival of at least 3 months.
Earlier treatment
Must have had at least 12 weeks of continuous anti-PD-1 or anti-PD-L1 treatment, alone or with other cancer therapies, and then the disease progressed on it or within 12 weeks after the last dose. For Part 2 only: earlier benefit shown as CR or PR at any time, or SD lasting at least 6 months.

Main reasons for not taking part

  • Immune-related medical conditions that raise risk with pembrolizumab
  • Another cancer that is progressing or needed active treatment in the past 2 years
  • Known active brain or leptomeningeal metastases
  • Active autoimmune disease needing systemic treatment in the past 2 years
  • Immunodeficiency or systemic steroids above 10 mg/day

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Has histologically or cytologically confirmed advanced or metastatic solid tumor
  • Have received ≥12 weeks of continuous anti-PD-1 or anti-PD-L1 treatment administered as monotherapy or in combination with other anticancer therapies
  • Have demonstrated documented prior clinical benefit, defined as CR or PR at any time during treatment, or SD lasting ≥6 months (Part 2 only)
  • Must have subsequently developed radiographic disease progression while receiving anti-PD-1 or anti-PD-L1 treatment or within ≤12 weeks after the last dose of such treatment
  • At least 1 measurable lesion, as defined by RECIST v1.1
  • Estimated survival of ≥3 months
  • Have adequate bone marrow and organ function
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding

Who cannot take part

  • Any immune-related medical conditions that would put participants at greater risk when receiving pembrolizumab
  • Has received prior radiotherapy within 2 weeks for palliative bone-directed therapy and 4 weeks for all other radiotherapy
  • Has undergone major surgery within 4 weeks prior to the first dose of study treatment or has not adequately recovered from surgery or related complications
  • Has a diagnosis of immunodeficiency or use of systemic steroids >10 mg/day
  • Has received a live or live-attenuated vaccine within 30 days or a non-live vaccine within 7 days prior to the first dose of PLN-101095
  • Has a known additional malignancy that is progressing or has required active treatment within the past 2 years
  • Has an active autoimmune disease that has required systemic treatment in the past 2 years
  • Has significant cardiac disease
  • Has an active infection requiring systemic therapy (including uncontrolled HIV, Hepatitis B and C)
  • Has known active CNS metastases (brain and/or leptomeningeal metastases)

Where in United States

Also in 1 other country, 7 sites

  • Winship Cancer Institute of Emory UniversityAtlanta, United StatesContact: Pliant Therapeutics Medical MonitorTaking people
  • NEXT AustinAustin, United StatesContact: Pliant Therapeutics Medical MonitorTaking people
  • START - New JerseyEast Brunswick, United StatesContact: Pliant Therapeutics Medical MonitorTaking people
  • Swedish Cancer Institute Medical OncologyEdmonds, United StatesContact: Pliant Therapeutics Medical MonitorTaking people
  • Inova Schar Cancer InstituteFairfax, United StatesContact: Pliant Therapeutics Medical MonitorTaking people
  • NEXT VirginiaFairfax, United StatesContact: Pliant Therapeutics Medical MonitorTaking people
  • START Center for Clinical ResearchFort Worth, United StatesContact: Pliant Therapeutics Medical MonitorTaking people
  • South Texas Accelerated Research Therapeutics (START)Grand Rapids, United StatesContact: Pliant Therapeutics Medical MonitorTaking people
  • NEXT HoustonHouston, United StatesContact: Pliant Therapeutics Medical MonitorTaking people
  • University of Texas - MD Anderson Cancer CenterHouston, United StatesContact: Pliant Therapeutics Medical MonitorTaking people
  • START New York Long Island, LLCLake Success, United StatesContact: Pliant Therapeutics Medical MonitorTaking people
  • Tennessee OncologyNashville, United StatesContact: Pliant Therapeutics Medical MonitorTaking people
  • Rutgers Cancer Institute of New JerseyNew Brunswick, United StatesContact: Pliant Therapeutics Medical MonitorTaking people
  • Yale UniversityNew Haven, United StatesContact: Pliant Therapeutics Medical MonitorNo longer taking part
  • UT Health San Antonio's Mays Cancer CenterSan Antonio, United StatesContact: Pliant Therapeutics Medical MonitorTaking people
  • Avera Medical GroupSioux Falls, United StatesContact: Pliant Therapeutics Medical MonitorTaking people
  • Washington University MedicineSt Louis, United StatesContact: Pliant Therapeutics Medical MonitorTaking people
  • Georgetown University Medical CenterWashington D.C., United StatesContact: Pliant Therapeutics Medical MonitorTaking people
  • START Mountain RegionWest Valley City, United StatesContact: Pliant Therapeutics Medical MonitorTaking people
  • Carolina Cancer Research CenterWilson, United StatesContact: Pliant Therapeutics Medical MonitorTaking people

About the trial

What the trial wants to find out

This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory [primary resistance]) or relapsed [secondary resistance]) after at least 3 months from the start of treatment with pembrolizumab.

Read full original descriptionShow less

The study will consist of 2 main parts:

* Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design with accelerated titration * Part 2: Dose-expansion cohorts using Simon's 2-stage design

The 8 groups in the trial

  • Part 1 Dose Escalation - 250 mg BIDTreatment being tested

    Cohort 1 PLN-101095 250 mg BID in combination with pembrolizumab in participants with solid tumors

    Treatment: PLN-101095 and Pembrolizumab

  • Part 1 Dose Escalation - 500 mg BIDTreatment being tested

    PLN-101095 500 mg BID in combination with pembrolizumab in participants with solid tumors

    Treatment: PLN-101095 and Pembrolizumab

  • Part 1 Dose Escalation - 1000 mg BIDTreatment being tested

    PLN-101095 1000 mg BID in combination with pembrolizumab in participants with solid tumors

    Treatment: PLN-101095 and Pembrolizumab

  • Part 1 Dose Escalation - 1000 mg TIDTreatment being tested

    PLN-101095 1000 mg TID in combination with pembrolizumab in participants with solid tumors

    Treatment: PLN-101095 and Pembrolizumab

  • Part 1 Dose Escalation - 2000 mg BIDTreatment being tested

    PLN-101095 2000 mg BID in combination with pembrolizumab in participants with solid tumors

    Treatment: PLN-101095 and Pembrolizumab

  • Part 2 Dose Expansion - NSCLCTreatment being tested

    PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Non-small cell lung cancer (NSCLC)

    Treatment: PLN-101095 and Pembrolizumab

  • Part 2 Dose Expansion - ccRCCTreatment being tested

    PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Clear cell renal cell carcinoma (ccRCC)

    Treatment: PLN-101095 and Pembrolizumab

  • Part 2 Dose Expansion - TMB-high solid tumorsTreatment being tested

    PLN-101095 given as monotherapy and in combination with pembrolizumab in participants with Tumor mutational burden (TMB)-high solid tumors

    Treatment: PLN-101095 and Pembrolizumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on an Immune Checkpoint Inhibitor (FORTIFY)
Plain-language title
Tests PLN-101095 with pembrolizumab in adults with advanced solid tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
12 November 2026